1. Home
  2. LVO vs ENTX Comparison

LVO vs ENTX Comparison

Compare LVO & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LiveOne Inc.

LVO

LiveOne Inc.

HOLD

Current Price

$4.44

Market Cap

56.2M

ML Signal

HOLD

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.28

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LVO
ENTX
Founded
2009
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.2M
62.6M
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
LVO
ENTX
Price
$4.44
$1.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$11.50
$10.00
AVG Volume (30 Days)
76.3K
175.8K
Earning Date
02-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
78.57
N/A
EPS
N/A
0.25
Revenue
$114,405,000.00
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$23.04
N/A
P/E Ratio
N/A
$4.80
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.91
52 Week High
$6.04
$3.22

Technical Indicators

Market Signals
Indicator
LVO
ENTX
Relative Strength Index (RSI) 42.33 54.75
Support Level $3.95 $1.17
Resistance Level $5.55 $1.39
Average True Range (ATR) 0.36 0.13
MACD -0.05 0.02
Stochastic Oscillator 25.98 81.25

Price Performance

Historical Comparison
LVO
ENTX

About LVO LiveOne Inc.

LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: